Last reviewed · How we verify

Empagliflozin (Jardiance®) — Competitive Intelligence Brief

Empagliflozin (Jardiance®) (Empagliflozin (Jardiance®)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor. Area: Diabetes.

marketed SGLT2 inhibitor SGLT2 (sodium-glucose cotransporter 2) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Empagliflozin (Jardiance®) (Empagliflozin (Jardiance®)) — University Hospital Tuebingen. Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Empagliflozin (Jardiance®) TARGET Empagliflozin (Jardiance®) University Hospital Tuebingen marketed SGLT2 inhibitor SGLT2 (sodium-glucose cotransporter 2)
oral hypoglycemic agents oral hypoglycemic agents Queen Elizabeth II Health Sciences Centre marketed Oral hypoglycemic agents (multiple classes: sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors)
Oral administration of Ipragliflozin Oral administration of Ipragliflozin Asan Medical Center marketed SGLT2 inhibitor SGLT2 (sodium-glucose cotransporter 2)
A5 A5 Breath of Life International Pharma Ltd marketed SGLT2 inhibitor SGLT2
Standard treatment strategy Standard treatment strategy Fundación para la Investigación del Hospital Clínico de Valencia marketed SGLT2 inhibitor SGLT2
Canagliflozin - SGLT2i Canagliflozin - SGLT2i Royal Devon and Exeter NHS Foundation Trust marketed SGLT2 inhibitor SGLT2 (sodium-glucose cotransporter 2)
Weight Based Group Weight Based Group University of Colorado, Denver marketed SGLT2 inhibitor SGLT2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor class)

  1. Daewon Pharmaceutical Co., Ltd. · 13 drugs in this class
  2. Qilu Pharmaceutical Co., Ltd. · 10 drugs in this class
  3. Takeda · 10 drugs in this class
  4. Taejoon Pharmaceutical Co., Ltd. · 9 drugs in this class
  5. Hanmi Pharmaceutical Company Limited · 9 drugs in this class
  6. Addpharma Inc. · 9 drugs in this class
  7. GlaxoSmithKline · 7 drugs in this class
  8. AO GENERIUM · 7 drugs in this class
  9. Merck Sharp & Dohme LLC · 7 drugs in this class
  10. Nobelpharma · 6 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Empagliflozin (Jardiance®) — Competitive Intelligence Brief. https://druglandscape.com/ci/empagliflozin-jardiance. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: